Digital Quantification of Potential Therapeutic Target RNAs
November 7, 2013
David Dodd, PhD
Department of Pharmacology
Univ. of Texas, Southwestern Medical Center at Dallas
Since its introduction Droplet Digital™ PCR (ddPCR™) technology has transformed multiple fields of research, including infectious disease, cancer biomarker analysis, and genomic variation analysis. In this seminar, Dr. David Dodd describes the application of ddPCR in his research studies with Prof. David Corey and colleagues at UT Southwestern Medical Center at Dallas. The Corey Lab focuses on using antisense oligonucleotides and duplex RNAs to control gene expression in human cancer cells.
The Droplet Digital PCR system allows for the quantification of target DNA with unrivaled precision by partitioning samples into 20,000 nanoliter-sized droplets. After PCR on a thermal cycler, PCR-positive and PCR-negative droplets are counted to provide absolute quantification of the target DNA.
The QX200™ Droplet Digital PCR system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.
About the speaker:
Dr. David Dodd received his PhD in Organic Chemistry at the University of Western Ontario. He is currently a Postdoctoral Fellow in the Department of Pharmacology, Univ. of Texas, Southwestern Medical Center at Dallas with Dr. David Corey. The research of Dr. Dodd focusses on investigating the molecular mechanisms and role of nuclear RNAs in gene regulation.
Find the latest quality management system certificates for various Bio-Rad locations worldwide.